Pleural Mesotheliomas
Oncology·MeSH: Mesothelioma, Malignant
Prevalence
1.0 / 100K
Incidence
0.9 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Fianlimab | Merus N.V. (MRUS) |
Frequently asked questions
How many drugs are in development for Pleural Mesotheliomas?
BioSniper tracks 1 drug in development for Pleural Mesotheliomas across 1 company.
How many clinical trials target Pleural Mesotheliomas?
There are 1 clinical trial targeting Pleural Mesotheliomas tracked by BioSniper.
What is the prevalence of Pleural Mesotheliomas?
The estimated prevalence of Pleural Mesotheliomas is approximately 1.0 per 100,000 population.
Deep-dive into Pleural Mesotheliomas
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis